Rigshospitalet

The research at this site explores innovative approaches for chronic obstructive pulmonary disease (COPD), targeting patients with severe airflow limitation to enhance long‑term outcomes.

• Eosinophil‑guided reduction of inhaled corticosteroids
• Azithromycin to lower COPD exacerbations and mortality
• Management strategies for GOLD class E COPD

With a team of 30 investigators, the studies aim to refine therapy selection and reduce hospital admissions, contributing valuable evidence for clinicians worldwide.

At Rigshospitalet, investigators are evaluating post‑myocardial infarction care, focusing on the impact of beta‑blocker treatment and comprehensive cardiovascular risk reduction.

• Beta‑blocker therapy after myocardial infarction without reduced ejection fraction
• Composite outcome monitoring of recurrent MI, stroke, and heart failure
• Strategies to prevent malignant ventricular arrhythmia and cardiac arrest

The program brings together 30 experts to generate data that could shape future guidelines for heart attack survivors across Europe.